244 related articles for article (PubMed ID: 22879932)
1. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.
Gong R; Wang Y; Ying T; Dimitrov DS
PLoS One; 2012; 7(8):e42288. PubMed ID: 22879932
[TBL] [Abstract][Full Text] [Related]
2. A large human domain antibody library combining heavy and light chain CDR3 diversity.
Chen W; Zhu Z; Feng Y; Dimitrov DS
Mol Immunol; 2010 Jan; 47(4):912-21. PubMed ID: 19883941
[TBL] [Abstract][Full Text] [Related]
3. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor.
Gong R; Wang Y; Feng Y; Zhao Q; Dimitrov DS
J Biol Chem; 2011 Aug; 286(31):27288-93. PubMed ID: 21669873
[TBL] [Abstract][Full Text] [Related]
4. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.
Wang Y; Kapoor P; Parks R; Silva-Sanchez A; Alam SM; Verkoczy L; Liao HX; Zhuang Y; Burrows P; Levinson M; Elgavish A; Cui X; Haynes BF; Schroeder H
Immunogenetics; 2016 Feb; 68(2):145-55. PubMed ID: 26687685
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
[TBL] [Abstract][Full Text] [Related]
7. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
[TBL] [Abstract][Full Text] [Related]
8. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
[TBL] [Abstract][Full Text] [Related]
9. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain.
Chen W; Zhu Z; Feng Y; Xiao X; Dimitrov DS
J Mol Biol; 2008 Oct; 382(3):779-89. PubMed ID: 18687338
[TBL] [Abstract][Full Text] [Related]
10. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
11. Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics.
Ching KH; Berg K; Reynolds K; Pedersen D; Macias A; Abdiche YN; Harriman WD; Leighton PA
MAbs; 2021; 13(1):1862451. PubMed ID: 33491549
[TBL] [Abstract][Full Text] [Related]
12. CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies.
Fernández-Quintero ML; Kroell KB; Grunewald LJ; Fischer AM; Riccabona JR; Liedl KR
MAbs; 2022; 14(1):2024118. PubMed ID: 35090383
[TBL] [Abstract][Full Text] [Related]
13. A novel heavy domain antibody library with functionally optimized complementarity determining regions.
Mandrup OA; Friis NA; Lykkemark S; Just J; Kristensen P
PLoS One; 2013; 8(10):e76834. PubMed ID: 24116173
[TBL] [Abstract][Full Text] [Related]
14. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
15. An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding.
Cao G; Gao X; Zhan Y; Wang Q; Zhang Z; Dimitrov DS; Gong R
MAbs; 2020; 12(1):1689027. PubMed ID: 31795802
[TBL] [Abstract][Full Text] [Related]
16. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
17. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors.
Xiao X; Feng Y; Vu BK; Ishima R; Dimitrov DS
Biochem Biophys Res Commun; 2009 Sep; 387(2):387-92. PubMed ID: 19615335
[TBL] [Abstract][Full Text] [Related]
18. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
19. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.
Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS
MAbs; 2016; 8(4):761-74. PubMed ID: 26963639
[TBL] [Abstract][Full Text] [Related]
20. Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.
Townsend S; Fennell BJ; Apgar JR; Lambert M; McDonnell B; Grant J; Wade J; Franklin E; Foy N; Ní Shúilleabháin D; Fields C; Darmanin-Sheehan A; King A; Paulsen JE; Hickling TP; Tchistiakova L; Cunningham O; Finlay WJ
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15354-9. PubMed ID: 26621728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
